Cytokinetics to Participate in the Jefferies Global Healthcare Conference

Core Insights - Cytokinetics will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20 AM Eastern Time [1] - The event will be accessible via a live webcast on the Cytokinetics website, with a replay available for 90 days post-event [2] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Aficamten is also being evaluated in additional trials for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) [3] - Cytokinetics is developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies [3]